Loading...
XSTO
NXTCL
Market cap7mUSD
May 16, Last price  
1.03SEK
1D
-1.90%
1Q
-68.98%
IPO
-69.64%
Name

NextCell Pharma AB

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
7.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
36.08%
Rev. gr., 5y
42.54%
Revenues
11m
+5.45%
6,960809,006517,203655,4131,812,1713,564,7013,912,0175,588,79710,113,47410,664,701
Net income
-42m
L+5.40%
-10,289,715-11,413,381-13,245,206-14,032,294-21,458,571-17,689,535-24,564,328-34,084,746-39,811,631-41,959,818
CFO
-38m
L-13.80%
-7,761,554-11,119,038-14,815,788-13,549,779-22,134,553-18,959,872-25,577,128-33,311,720-43,825,695-37,778,383

Profile

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
URL
https://www.nextcellpharma.com/
IPO date
Jul 13, 2017
Employees
15
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑082023‑082022‑082021‑082020‑082019‑082018‑082017‑082016‑082015‑08
Income
Revenues
10,665
5.45%
10,113
80.96%
5,589
42.86%
Cost of revenue
54,413
10,998
27,850
Unusual Expense (Income)
NOPBT
(43,748)
(885)
(22,261)
NOPBT Margin
Operating Taxes
1,193
(470)
Tax Rate
NOPAT
(43,748)
(2,078)
(21,791)
Net income
(41,960)
5.40%
(39,812)
16.80%
(34,085)
38.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
33,832
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
3,816
3,020
2,185
Other long-term liabilities
Net debt
(54,794)
(58,028)
(105,117)
Cash flow
Cash from operating activities
(37,778)
(43,826)
(33,312)
CAPEX
(83)
(4,099)
(7,590)
Cash from investing activities
(84)
(4,102)
(9,374)
Cash from financing activities
34,627
836
608
FCF
(47,355)
5,847
(31,189)
Balance
Cash
46,791
50,025
97,117
Long term investments
8,003
8,003
8,000
Excess cash
54,261
57,522
104,837
Stockholders' equity
(154,726)
(120,702)
(80,891)
Invested Capital
226,141
199,450
198,377
ROIC
ROCE
EV
Common stock shares outstanding
73,091
34,380
34,380
Price
Market cap
EV
EBITDA
(42,773)
(437)
(21,803)
EV/EBITDA
Interest
1
3
14
Interest/NOPBT